Aagami to represent several client partnering opportunities during JPM week 2020 in San Francisco

Published : 09 Dec 2019

Aagami is proud to announce that it will be representing multiple clients with respect to the partnering of their assets and technologies, during JPM week 2020 in San Francisco.

These include:

              1. Available for Licensing: DriDose® - a Platform Technology for the delivery of a dry powder drug formulation into the nasal cavity.
              2. Available for Licensing: Diabetic drug for the treatment of severe hypoglycaemic reactions using Dridose® nasal dry powder formulation; successfully completed a proof of concept clinical trial.
              3. Available for IP Acquisition: Next-Generation PEGylation(PharmaPEG®) technology & associated assets.
              4. Seeking Investment / Partnering: Drug to treat alcohol poisoning(Breakthrough, life-saving); Another Drug to prevent hangover and Asian Flush; quick to market solution which works safely and efficiently.
              5. Seeking Investment & Partnering: Algae Technology - for Beta Carotene, Lutein, DHA and others (Innovative Process and Cost Optimized).
              6. Available for Licensing: Selection Technology using Bacteriocin-Immunity for Improved Microbial (E. coli.) Fermentation.

              Should any of these be of your interest, please contact godwyn@aagami.com (Godwyn Francis, VP, Aagami).

              ×
              Twitter